1

André Larente on DIAGNOS’ Partnership with EssilorLuxottica to Expand AI Retinal Analysis and Offers Updates on Regulatory Approvals

written by InvestorNews | September 9, 2024

September 09, 2024 — In a recent interview with InvestorNews host Pat Bolland, André Larente, President, CEO, and Director of DIAGNOS Inc. (TSXV: ADK | OTCQB: DGNOF), discussed the company’s journey in the healthcare AI sector, focusing on their flagship product, the Computer Assisted Retina Analysis (CARA). DIAGNOS has transitioned from multiple AI applications to specialize solely in retinal analysis, which has been under development for over eight years. Larente emphasized the company’s efforts to ensure that CARA is adaptable for various cultures by collecting data from over 400,000 patients across 14 countries. He noted, “We decided to drop all the other applications we were doing and really specialize in this healthcare phenomenon,” highlighting the company’s focus on early detection of diabetic retinopathy, hypertensive retinopathy, and age-related macular degeneration (AMD). Larente also underscored the cost-effectiveness of CARA, with general tests priced at $10 and additional tests at $5, making it accessible for optometrists and patients alike.

A significant part of DIAGNOS’ recent developments is its strategic partnership with EssilorLuxottica, the largest single player in the global eyewear market, which dominates the industry with approximately 300,000 optometry sites worldwide. Larente explained the importance of this agreement, stating, “We can’t hire 1,000 salespeople… they have established relationships that you can’t beat.” This partnership allows DIAGNOS to expand its market reach, particularly in North America, where Essilor will address 5,500 stores in Canada and 65,000 in the US. Additionally, Larente discussed DIAGNOS’ plans to obtain regulatory approvals from Health Canada and the US FDA for their suite of retinal analysis tests, which are expected to be approved by the end of the year. He pointed out that regulatory approvals and certifications, such as the recently obtained ISO 13485/MDSAP audit, are crucial in ensuring the company’s credibility in the healthcare market.

To access the complete interview, click here

Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here

About DIAGNOS Inc.

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

To learn more about DIAGNOS Inc., click here

Disclaimer: DIAGNOS Inc. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. (“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.